UBS has reaffirmed its Buy rating and $180 price target for Johnson & Johnson, despite recent legal setbacks, including a federal judge's rejection of the company's bankruptcy strategy to settle talc-related lawsuits. The firm remains optimistic about the company's potential success in traditional litigation, as Johnson & Johnson explores alternative options. Additionally, the company reported promising results from its Phase 3 MARIPOSA study for lung cancer treatments and new data on nipocalimab for myasthenia gravis, highlighting its commitment to medical advancements amid ongoing legal challenges.